Beckman Coulter Diagnostics’ Access MeMed BV assay, a test that helps clinicians differentiate between bacterial and viral infections, is now approved under the IVDR.
Beckman Coulter has partnered with MeMed, a leader in advanced host response technologies, to bring the MeMed BV test into core laboratory settings. MeMed’s mission is to transform patient care by interpreting immune system signals and translating host-response data into clinical insights to support clinicians’ decision-making.
Clinicians have published that use of the MeMed BV test has resulted in improved clinical decision-making, helped them to reduce unnecessary antibiotic use, and supported antimicrobial stewardship efforts.
Validated for use across Beckman Coulter’s installed base of DxI 9000 and Access 2 immunoassay analysers, the Access MeMed BV assay enables fast, reliable infection differentiation while leveraging laboratories’ existing infrastructure and workflows.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.